SCHEMBL6136500

SCHEMBL6136500

CC(NC(=O)Cc1ccc(Cl)c(Cl)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
S1PR1 P21453 1/20 0.47
S1PR3 Q99500 1/20 0.46
SHMT1 P34896 1/20 0.46
SHMT2 P34897 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
DGAT1 O75907 1/20 0.45
GRN P28799 1/20 0.45
SORT1 Q99523 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136504 1.00 L3MBTL1 (0.49) L3MBTL1LMNAHTTMEN1MAPT
SCHEMBL8802561 0.87 L3MBTL1 (0.48) L3MBTL1LMNAHTTMEN1MAPT
SCHEMBL6136678 0.84 S1PR3 (0.48) L3MBTL1LMNAHTTMEN1MAPT
SCHEMBL6136330 0.83 CNR2 (0.61) L3MBTL1LMNAMEN1KMT2ASHMT1
SCHEMBL6136328 0.83 CNR2 (0.61) L3MBTL1LMNAMEN1KMT2ASHMT1
SCHEMBL4414749 0.82 L3MBTL1 (0.44) L3MBTL1LMNAHTTMEN1MAPT
SCHEMBL6136304 0.82 L3MBTL1 (0.44) L3MBTL1LMNAHTTMEN1MAPT
SCHEMBL4414837 0.81 ALDH1A1 (0.52) MEN1KMT2ASHMT1SHMT2SMN1; SMN2
SCHEMBL4414835 0.81 ALDH1A1 (0.52) MEN1KMT2ASHMT1SHMT2SMN1; SMN2
SCHEMBL6136711 0.80 THRA (0.46) SHMT1SHMT2SMN1; SMN2ALDH1A1GRN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0951464-B1 N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-05-11 EP claimed
US-6767918-B2 ALZHEIMER'S DISEASE ATHENA NEUROSCIENCES, INC. 2004-07-27 US disclosed
US-20030191119-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds WU JING (US) 2003-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191119-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds APP, BACE1, IAPP L3MBTL1 4297/4885LMNA 1921/4885HTT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.